GVR Report cover Antibodies Contract Manufacturing Market Size, Share & Trends Report

Antibodies Contract Manufacturing Market Size, Share & Trends Analysis Report, By Product (Monoclonal Antibodies, Polyclonal Antibodies, Others), By Source, By End Use, By Region, And Segment Forecasts, 2022 - 2030

  • Published Date: Apr 2022
  • Report ID: GVR-4-68039-920-3
  • Number of Pages: 100
  • Format: Electronic (PDF)
  • Historical Data: 2017 - 2020

Report Overview

The global antibodies contract manufacturing market size was valued at USD 12.0 billion in 2021 and is anticipated to expand at a compound annual growth rate (CAGR) of 13.1% during the forecast period. The rising emphasis of biopharmaceutical & biotechnology companies on the production of antibody therapeutics is the primary factor driving the growth. These therapeutics are extremely effective in the treatment of cancer, rheumatoid arthritis, and other chronic diseases. Consequently, there is a surge in demand for the production of therapeutic antibodies, leading to the growth of the market. Moreover, monoclonal antibody therapy is used as a treatment for COVID-19, leading to an increase in the demand for antibody production. The ongoing COVID-19 pandemic has positively impacted the market.

U.S. Antibodies Contract Manufacturing Market, by Product 2017 - 2030 (USD Billion)

As the development of mRNA vaccines and subsequent manufacturing at a global scale to respond to the COVID-19 pandemic represents a leap forward in antibody production. Currently, there are around 220 mRNA candidates in development and nucleotide-based therapies and vaccines are expected to grow at a higher growth rate. The pandemic has focused CDMO activity on rapid scale-up of production for commercial supply, but the demand for outsourced early phase development services and technology is growing in line with this new generation of molecules.

Key players have been involved in strategic partnerships for the development of treatment against COVID-19. For instance, in May 2020, Lonza announced a strategic collaboration agreement for ten years with Moderna to empower the manufacture of Spikevax COVID-19 vaccine and further Moderna products in the future.

Many pharmaceutical and biotechnology businesses have increased their R&D efforts to create biologics, such as monoclonal antibodies, as these are becoming more popular as a select therapy for various lung indications, including lung cancer, asthma, and lung infections. Thus, focusing on R&D is a critical strategy for the company's long-term success.

Several pharmaceutical and biotechnology businesses are forming strategic alliances and collaborations in order to obtain market leadership. Also, major players are expanding their global footprint; for example, in January 2022, Fujifilm Diosynth Biotechnologies announced the acquisition of Atara Biotherapeutics, Inc., a company involved in cell therapy manufacturing, thus boosting the product portfolio for advanced therapies.

Biopharmaceutical manufacturing is recognized as a leading sector in terms of growth potential. Many healthcare entities believe that this sector would be one of the top 10 revenue generators in the coming years. Moreover, the market players are making continuous efforts for the development of this sector to meet the increasing demand for bio-based pharmaceuticals, which in turn, is anticipated to result in a surge of CMOs for biopharmaceutical production. This healthy growth of biopharmaceuticals has resulted in the development of a large product pipeline.

Understanding the cost-effectiveness associated with contract manufacturing, many firms have begun to outsource parts of their biopharmaceutical manufacturing to contract manufacturers. There are many biopharmaceutical products, including recombinant proteins, monoclonal antibodies, and engineered antibody-like biomolecules approved by the U.S. FDA. The number of approvals increased during the pandemic when the U.S. FDA gave Emergency Use Authorization (EUA). For instance, EUA was granted for monoclonal antibodies treatment, which included Casirivimab and Imdevimab.

Product Insights

Monoclonal antibodies dominated the product segment with a 70.9% share as of 2021. Based on product, the market is segmented into monoclonal antibodies, polyclonal antibodies, and others. Monoclonal antibody (mAb) formulations have been more popular as a select therapy for various lung indications, including lung cancer, lung infections, and asthma. They are also proven to be effective in treating COVID-19 infections; Casirivimab and imdevimab are designed specifically to block the virus’ attachment and entry into human cells.

Moreover, CMOs are collaborating more with biopharmaceutical companies for the production and development of monoclonal antibodies. For instance, WuXi Biologics collaborated with Vir Biotechnology, Inc. for the production of antibodies, especially required for the production of sotrovimab for the treatment of COVID-19.

Rising awareness amongst physicians and patients with regards to the applications of mAb therapy is contributing toward further growth. Additionally, the usage rate for mAb therapy is expected to be boosted after receiving approval for the blockbuster mAbs for a variety of indications during the forecast period. For example, revenue-generating drugs such as Remicade, Avastin, Herceptin, and Rituxan, with FDA approval for an array of conditions such as cancer, Crohn's disease, rheumatoid arthritis, ulcerative colitis, etc., further boost the patient base. Thus, monoclonal antibodies accounted for the largest share in 2021.

Source Insights

The mammalian source segment accounted for the largest share of 58.5% in the market as of 2021. Based on the source, the market is segmented into mammalian and microbial. With the growing demand for biopharmaceutical contract manufacturing services, several CMOs are expanding their capacity for mammalian cell culture production. In mAb production, the mammalian cell expression system is the most preferred choice, owing to the primary advantage that the cellular mechanism is modified for the processing, production, and secretion of extremely complex molecules.

Major players are investing and expanding their mammalian cell expression system manufacturing facilities. There are a number of CMOs, such as Lonza and Charles River, that offer services for production using mammalian cell lines. These firms are making significant investments in advancing their mammalian cell culture manufacturing facilities for antibody development. For instance, WuXi Biologics has over 150,000L of bioreactor capacity for mammalian cell culture supply, and the company will be increasing the capacity to 430,000L by 2023.

Moreover, the introduction of technologies for the growth of mammalian expression system titers and yields are also developed. Companies such as KBI Biopharma introduced single-use process technologies for improving their mammalian manufacturing areas. An enormous percentage of biopharmaceutical products that are in pipeline are mammalian expressed. With the growth in mammalian system titers and yields, facilities are engaged in homogenizing their mammalian systems. This is poised to benefit mammalian-based source market growth.

End-user Insights

The biopharmaceutical companies segment accounted for the largest share in 2021 with over 67.2% and is also the fastest-growing during the forecast period. Based on end-user, the market is classified into biopharmaceutical companies, research laboratories, and others. Biopharmaceutical companies play a significant role in the development of innovative treatments for patients worldwide.

The market is mainly driven by the rising geriatric population, escalating chronic diseases, and increasing acceptance among patients for new and advanced treatments. The capability of biopharmaceutical products to treat previously untreatable conditions has introduced innovative drugs into the market.

Global Antibodies Contract Manufacturing Market Share, by End User, 2021 (%)

The constant requirement for innovation in the treatment models and the use of advanced treatments such as monoclonal antibody therapy is leading to an increase in R&D investment for biopharmaceuticals. This in turn is leading to collaboration among biopharmaceuticals and CMOs for the development of advanced treatments; thus, leading to major share and is expected to further influence segment growth.

Regional Insights

North America dominated the market in 2021 with a share of around 34.3%. This is attributable to the widespread manufacturing of biopharmaceuticals in the region and the presence of a substantial number of CDMO/CMO facilities. State and other laws pertaining to the development of biologics in the region are expected to significantly impact the progress of biopharmaceutical contract manufacturing in this region.

The Asia region is projected to be the fastest-growing during the forecast period. This growth can be attributed to factors, such as regulatory changes, improving infrastructure, and the presence of a large number of potential study subjects. Several biopharma companies from the U.S. are considering developing pharma products in Asian countries owing to the growing costs of R&D in their home country. Low-cost production facilities and cheap labor are available in Asian countries. The cost of production in Asian countries is 30 to 60% lower than that in Western countries, thus driving the antibody contract manufacturing market.

Key Companies & Market Share Insights

International partnerships are a key strategy witnessed among players. For instance, CMOs in the U.S. are increasingly collaborating with players in the Swiss pharmaceutical sector. Additionally, expansion of the major CMOs to meet the requirements as well as stay ahead of the competition is also witnessed. Some of the prominent players in the global antibody contract manufacturing market include:

  • Lonza

  • Samsung Biologics

  • WuXi Biologics.

  • Charles River Laboratories

  • FUJIFILM Holdings Corporation

  • Boehringer Ingelheim Biopharmaceuticals GmbH.

  • AGC Biologics

  • Cytovance Biologics, Inc.

  • EMERGENT

  • Thermo Fisher Scientific

  • Labcorp Drug Development

  • Catalent, Inc.

Antibody Contract Manufacturing Market Report Scope

Report Attribute

Details

Market size value in 2022

USD 13.4 billion

Revenue forecast in 2030

USD 35.9 billion

Growth Rate

CAGR of 13.1% from 2022 to 2030

Base year for estimation

2021

Historical data

2017 - 2020

Forecast period

2022 - 2030

Quantitative units

Revenue in USD million & CAGR from 2022 to 2030

Segments covered

Product, source, end-user, region

Regional scope

North America; Europe; Asia Pacific; Latin America & MEA

Country scope

U.S.; Canada; U.K.; Germany; France; Spain; Italy; China; India; Japan; Australia; South Korea; Brazil; Mexico; Argentina; Colombia; Chile; South Africa; UAE; Egypt

Key companies profiled

Lonza; Samsung Biologics; WuXi Biologics.; Charles River Laboratories; FUJIFILM Holdings Corporation; AGC Biologics; Cytovance Biologics, Inc.; EMERGENT; Thermo Fisher Scientific; Labcorp Drug Development; Catalent, Inc; Boehringer Ingelheim Biopharmaceuticals GmbH.

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Customization scope

Free report customization (equivalent up to 8 analyst working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

 

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, & country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2017 to 2030. For the purpose of this study, Grand View Research has segmented the global antibody contract manufacturing market report based on product, source, end-user, and region:

  • Product Outlook (Revenue, USD Million, 2017 - 2030)

    • Monoclonal Antibodies

    • Polyclonal Antibodies

    • Others

  • Source Outlook (Revenue, USD Million, 2017 - 2030)

    • Mammalian

    • Microbial

  • End-User Outlook (Revenue, USD Million, 2017 - 2030)

    • Biopharmaceutical Companies

    • Research Laboratories

    • Others

  • Region Outlook (Revenue, USD Million, 2017 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

      • France

      • Italy

      • Spain

    • Asia Pacific

      • China

      • Japan

      • India

      • Australia

      • South Korea

    • Latin America

      • Brazil

      • Mexico

      • Argentina

      • Colombia

      • Chile

    • MEA

      • South Africa

      • UAE

      • Egypt

Frequently Asked Questions About This Report

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.